Concepts (180)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 29 | 2025 | 3110 | 2.430 |
Why?
|
| Genetic Predisposition to Disease | 21 | 2025 | 2465 | 1.600 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2017 | 2484 | 0.720 |
Why?
|
| Genetic Loci | 3 | 2016 | 260 | 0.700 |
Why?
|
| Estrogen Receptor alpha | 3 | 2017 | 155 | 0.570 |
Why?
|
| Triple Negative Breast Neoplasms | 4 | 2023 | 190 | 0.560 |
Why?
|
| BRCA1 Protein | 7 | 2019 | 214 | 0.550 |
Why?
|
| Germ-Line Mutation | 4 | 2019 | 381 | 0.540 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2017 | 8 | 0.530 |
Why?
|
| Mutation | 9 | 2023 | 4272 | 0.520 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2017 | 70 | 0.500 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2017 | 215 | 0.470 |
Why?
|
| Vitamin D | 1 | 2017 | 272 | 0.450 |
Why?
|
| BRCA2 Protein | 5 | 2019 | 173 | 0.430 |
Why?
|
| Nigeria | 8 | 2025 | 162 | 0.400 |
Why?
|
| Estrogen Receptor beta | 1 | 2012 | 26 | 0.370 |
Why?
|
| Genetic Testing | 3 | 2018 | 565 | 0.370 |
Why?
|
| Glypicans | 1 | 2012 | 7 | 0.360 |
Why?
|
| Microsatellite Repeats | 1 | 2012 | 150 | 0.360 |
Why?
|
| Female | 34 | 2025 | 48702 | 0.360 |
Why?
|
| Genome-Wide Association Study | 5 | 2023 | 1762 | 0.360 |
Why?
|
| Receptors, Androgen | 1 | 2012 | 119 | 0.350 |
Why?
|
| Genetic Association Studies | 6 | 2017 | 300 | 0.350 |
Why?
|
| Telomerase | 1 | 2011 | 67 | 0.340 |
Why?
|
| Case-Control Studies | 9 | 2025 | 1931 | 0.340 |
Why?
|
| Mass Screening | 2 | 2018 | 696 | 0.320 |
Why?
|
| Biomarkers, Tumor | 3 | 2024 | 1660 | 0.320 |
Why?
|
| Gene Fusion | 1 | 2010 | 40 | 0.320 |
Why?
|
| Middle Aged | 20 | 2025 | 27573 | 0.310 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2011 | 298 | 0.300 |
Why?
|
| Genotype | 6 | 2023 | 1866 | 0.300 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2011 | 304 | 0.300 |
Why?
|
| DNA-Binding Proteins | 2 | 2016 | 1234 | 0.300 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 537 | 0.280 |
Why?
|
| Alleles | 4 | 2017 | 1139 | 0.280 |
Why?
|
| Carcinoma | 1 | 2011 | 439 | 0.280 |
Why?
|
| Adult | 18 | 2025 | 27918 | 0.270 |
Why?
|
| Ovarian Neoplasms | 2 | 2014 | 797 | 0.270 |
Why?
|
| Up-Regulation | 3 | 2024 | 730 | 0.270 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 740 | 0.250 |
Why?
|
| Humans | 35 | 2025 | 93515 | 0.250 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2024 | 1338 | 0.230 |
Why?
|
| Membrane Proteins | 1 | 2011 | 1264 | 0.220 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 1173 | 0.220 |
Why?
|
| DNA Mutational Analysis | 4 | 2019 | 543 | 0.200 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2024 | 398 | 0.180 |
Why?
|
| Gene Frequency | 3 | 2016 | 700 | 0.180 |
Why?
|
| Gene Expression Profiling | 4 | 2024 | 1518 | 0.180 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2022 | 122 | 0.170 |
Why?
|
| DNA Methylation | 2 | 2016 | 697 | 0.170 |
Why?
|
| MicroRNAs | 2 | 2016 | 580 | 0.170 |
Why?
|
| Risk | 2 | 2012 | 657 | 0.160 |
Why?
|
| Lung Neoplasms | 1 | 2012 | 2365 | 0.150 |
Why?
|
| Epigenesis, Genetic | 3 | 2018 | 555 | 0.150 |
Why?
|
| Neoplasms, Basal Cell | 1 | 2018 | 10 | 0.140 |
Why?
|
| CpG Islands | 2 | 2016 | 168 | 0.140 |
Why?
|
| Homologous Recombination | 1 | 2018 | 57 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 2 | 2011 | 893 | 0.130 |
Why?
|
| RNA, Long Noncoding | 1 | 2018 | 129 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 3476 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2016 | 54 | 0.120 |
Why?
|
| Ribonuclease III | 1 | 2016 | 17 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 2 | 2016 | 962 | 0.120 |
Why?
|
| Receptors, Progesterone | 1 | 2016 | 196 | 0.120 |
Why?
|
| Carcinogenesis | 1 | 2017 | 235 | 0.110 |
Why?
|
| Odds Ratio | 2 | 2013 | 711 | 0.110 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 482 | 0.100 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2013 | 27 | 0.100 |
Why?
|
| Base Sequence | 3 | 2012 | 2220 | 0.100 |
Why?
|
| Genomics | 1 | 2019 | 848 | 0.100 |
Why?
|
| Risk Factors | 7 | 2025 | 5899 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2013 | 78 | 0.100 |
Why?
|
| Cameroon | 2 | 2025 | 19 | 0.100 |
Why?
|
| Uganda | 2 | 2025 | 46 | 0.090 |
Why?
|
| Confidence Intervals | 1 | 2013 | 217 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2013 | 127 | 0.090 |
Why?
|
| Sequence Analysis, RNA | 2 | 2018 | 255 | 0.090 |
Why?
|
| Hereditary Breast and Ovarian Cancer Syndrome | 1 | 2012 | 12 | 0.090 |
Why?
|
| Cell Line, Tumor | 3 | 2016 | 2755 | 0.090 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 1 | 2011 | 18 | 0.090 |
Why?
|
| Logistic Models | 2 | 2013 | 1243 | 0.090 |
Why?
|
| Codon, Nonsense | 1 | 2011 | 47 | 0.090 |
Why?
|
| Family Health | 1 | 2011 | 153 | 0.080 |
Why?
|
| China | 1 | 2012 | 264 | 0.080 |
Why?
|
| Ataxin-7 | 1 | 2010 | 5 | 0.080 |
Why?
|
| Diabetes Complications | 1 | 2012 | 170 | 0.080 |
Why?
|
| Heredity | 1 | 2010 | 20 | 0.080 |
Why?
|
| Genes, BRCA2 | 1 | 2011 | 162 | 0.080 |
Why?
|
| Protein Isoforms | 1 | 2011 | 295 | 0.080 |
Why?
|
| Genes, BRCA1 | 1 | 2011 | 191 | 0.080 |
Why?
|
| Breast Neoplasms, Male | 1 | 2010 | 31 | 0.080 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 478 | 0.080 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 2 | 2023 | 25 | 0.080 |
Why?
|
| Chromosome Mapping | 1 | 2013 | 1052 | 0.080 |
Why?
|
| Haplotypes | 1 | 2011 | 647 | 0.080 |
Why?
|
| Gene Rearrangement | 1 | 2010 | 168 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 985 | 0.070 |
Why?
|
| Poly A | 1 | 2008 | 20 | 0.070 |
Why?
|
| Pedigree | 1 | 2010 | 961 | 0.070 |
Why?
|
| DNA Copy Number Variations | 2 | 2022 | 192 | 0.070 |
Why?
|
| Aged | 5 | 2024 | 20434 | 0.070 |
Why?
|
| Smoking | 1 | 2012 | 648 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2010 | 502 | 0.070 |
Why?
|
| Signal Transduction | 1 | 2017 | 3502 | 0.060 |
Why?
|
| Chicago | 1 | 2010 | 1464 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2023 | 3054 | 0.060 |
Why?
|
| Prognosis | 3 | 2024 | 3911 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 537 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1229 | 0.050 |
Why?
|
| Prevalence | 2 | 2019 | 1321 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2025 | 2441 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2023 | 196 | 0.040 |
Why?
|
| Breast | 1 | 2023 | 294 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2022 | 2026 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 554 | 0.040 |
Why?
|
| Molecular Epidemiology | 1 | 2019 | 57 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 446 | 0.040 |
Why?
|
| Hypoxia | 1 | 2024 | 675 | 0.040 |
Why?
|
| APOBEC Deaminases | 1 | 2018 | 5 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2023 | 456 | 0.040 |
Why?
|
| Microarray Analysis | 1 | 2018 | 96 | 0.040 |
Why?
|
| Transcriptome | 1 | 2024 | 762 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 76 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 889 | 0.030 |
Why?
|
| Whole Genome Sequencing | 1 | 2018 | 109 | 0.030 |
Why?
|
| Exome | 1 | 2018 | 141 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2018 | 4560 | 0.030 |
Why?
|
| Cadherins | 1 | 2018 | 180 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2012 | 2910 | 0.030 |
Why?
|
| High Mobility Group Proteins | 1 | 2016 | 27 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2018 | 476 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2018 | 280 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2016 | 120 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2016 | 201 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 454 | 0.030 |
Why?
|
| Mammography | 1 | 2018 | 458 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2016 | 282 | 0.030 |
Why?
|
| Genetics, Population | 1 | 2018 | 439 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1524 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 486 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1175 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2016 | 413 | 0.030 |
Why?
|
| Male | 3 | 2012 | 44557 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2015 | 524 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2016 | 439 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 1448 | 0.030 |
Why?
|
| Age of Onset | 1 | 2014 | 342 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2014 | 147 | 0.030 |
Why?
|
| Premenopause | 1 | 2013 | 63 | 0.020 |
Why?
|
| Parity | 1 | 2013 | 97 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 2017 | 0.020 |
Why?
|
| Apoptosis | 1 | 2019 | 1721 | 0.020 |
Why?
|
| Phenotype | 1 | 2019 | 2544 | 0.020 |
Why?
|
| Barbados | 1 | 2012 | 7 | 0.020 |
Why?
|
| Postpartum Period | 1 | 2013 | 159 | 0.020 |
Why?
|
| Mutation Rate | 1 | 2012 | 54 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2012 | 266 | 0.020 |
Why?
|
| Chromosome Breakpoints | 1 | 2010 | 15 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2013 | 811 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2010 | 209 | 0.020 |
Why?
|
| Introns | 1 | 2010 | 300 | 0.020 |
Why?
|
| Mice | 1 | 2023 | 12269 | 0.020 |
Why?
|
| Exons | 1 | 2010 | 450 | 0.020 |
Why?
|
| Expressed Sequence Tags | 1 | 2008 | 34 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2008 | 98 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 894 | 0.020 |
Why?
|
| Survival Rate | 1 | 2012 | 1948 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2008 | 278 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2008 | 517 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 691 | 0.010 |
Why?
|
| Histones | 1 | 2008 | 361 | 0.010 |
Why?
|
| Pregnancy | 1 | 2013 | 3147 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 7061 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 3830 | 0.010 |
Why?
|
| Gene Expression | 1 | 2008 | 1301 | 0.010 |
Why?
|
| Genome, Human | 1 | 2008 | 823 | 0.010 |
Why?
|
| Animals | 1 | 2023 | 28155 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2008 | 970 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 1768 | 0.010 |
Why?
|
| Young Adult | 1 | 2013 | 6930 | 0.010 |
Why?
|